![Charlotte Vedel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Charlotte Vedel
Direktor/Vorstandsmitglied bei CURASIGHT A/S
Vermögen: 56 047 $ am 31.05.2024
Aktive Positionen von Charlotte Vedel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CURASIGHT A/S | Direktor/Vorstandsmitglied | 01.01.2020 | - |
Independent Dir/Board Member | 01.01.2020 | - | |
Lactobio ApS | Geschäftsführer | 01.08.2017 | - |
Gründer | 01.08.2017 | - |
Karriereverlauf von Charlotte Vedel
Ehemalige bekannte Positionen von Charlotte Vedel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Novo Nordisk Fonden
![]() Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2017 | 01.01.2018 |
International N&H Denmark ApS
![]() International N&H Denmark ApS Food: Major DiversifiedConsumer Non-Durables DuPont Nutrition Biosciences ApS is engaged in the production of food enzymes, products and pharmaceutical grade excipients for food products. It operates through the following divisions: Enablers, BioActives, Sweeteners, Cultures, Genecor and Sales and Application Food Ingredients. The Enablers division develops, produces and markets emulsifiers, hydrocolloids, and tailored systems that enable food & beverage manufactureres to make appealing products. The BioActives division is comprised of the Cultures and Sweeteners divisions. It offers food cultures and protective solutions, speciality sweeteners, health ingredients, and microorganisms for agriculture and animal nutrition. The Genencor division develops innovative enzymes and bioproducts to reduce the environmental impact of the cleaning, textile, fuel, and chemical industries. The sales and Application food Ingredients division manages and budgets global key accounts. The company was founded in 1989 and is headquartered Copenhagen, Denmark | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2006 | 01.01.2017 |
Roche Innovation Center Copenhagen A/S
![]() Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2001 | 01.01.2003 |
Ausbildung von Charlotte Vedel
Technical University of Denmark | Doctorate Degree |
University of Ulster | Graduate Degree |
Statistik
International
Dänemark | 7 |
Vereinigtes Königreich | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Graduate Degree | 2 |
Chief Operating Officer | 2 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Miscellaneous | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CURASIGHT A/S | Health Technology |
Private Unternehmen | 4 |
---|---|
Lactobio ApS | |
Novo Nordisk Fonden
![]() Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Miscellaneous |
International N&H Denmark ApS
![]() International N&H Denmark ApS Food: Major DiversifiedConsumer Non-Durables DuPont Nutrition Biosciences ApS is engaged in the production of food enzymes, products and pharmaceutical grade excipients for food products. It operates through the following divisions: Enablers, BioActives, Sweeteners, Cultures, Genecor and Sales and Application Food Ingredients. The Enablers division develops, produces and markets emulsifiers, hydrocolloids, and tailored systems that enable food & beverage manufactureres to make appealing products. The BioActives division is comprised of the Cultures and Sweeteners divisions. It offers food cultures and protective solutions, speciality sweeteners, health ingredients, and microorganisms for agriculture and animal nutrition. The Genencor division develops innovative enzymes and bioproducts to reduce the environmental impact of the cleaning, textile, fuel, and chemical industries. The sales and Application food Ingredients division manages and budgets global key accounts. The company was founded in 1989 and is headquartered Copenhagen, Denmark | Consumer Non-Durables |
Roche Innovation Center Copenhagen A/S
![]() Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
- Börse
- Insiders
- Charlotte Vedel
- Erfahrung